No Data
Huaren pharmaceutical (300110.SZ): Currently, the product field has not yet involved traditional chinese medicine business.
Huaren Pharmaceutical (300110.SZ) stated on the investor interaction platform on November 28 that the company is mainly engaged in the research and development, production, and sales of peritoneal dialysis solution, respiratory system medications, large volume infusions (including non-PVC flexible bags, upright flexible bags, plastic bottles, glass bottles for large infusions), analgesic medications, active pharmaceutical ingredients, supporting medical packaging materials, and medical instruments. The current product areas do not involve traditional Chinese medicine business.
Huaren Pharmaceutical (300110.SZ): The wholly-owned subsidiary has obtained the medical instruments registration certificate for disposable tracheal intubation.
On November 27, Geldhui announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., recently received the "Medical Device Registration Certificate" for "Disposable Tracheal Tubes" issued by the Shandong Province Food and Drug Administration. The product models include HRQC-11, HRQC-12, HRQC-13, HRQC-14, HRQC-21, HRQC-22, HRQC-23, HRQC-24; with a total of 138 model specifications for establishing artificial airways during clinical anesthesia or emergencies.
Huaren Pharmaceutical (300110.SZ): The monkeypox virus testing kit has not yet obtained domestic registration certification and has not generated any orders.
Gelonghui, November 18th丨huaren pharmaceutical (300110.SZ) stated on the investor interaction platform that the monkeypox virus testing kit has not yet obtained domestic registration certification, and no order has been generated.
Huaren Pharmaceutical (300110.SZ): Hongta Innovation completes shareholding of 1.00% stake.
Gelonghui November 8th | huaren pharmaceutical (300110.SZ) announced that the company recently received a notice from Hongta innovation regarding the implementation of the shareholding reduction plan for huaren pharmaceutical. The above-mentioned shareholding reduction plan by Hongta innovation has been completed. Hongta innovation has cumulatively reduced its holding of the company's shares by 11,800,000 shares during this shareholding reduction plan period, with a reduction rate of 1.00%.
Huaren Pharmaceutical (300110.SZ): Sodium phosphinate injection obtained pharmaceutical registration certificate.
On November 5th, Hua Ren Pharmaceutical (300110.SZ) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the "Sodium Phosphonoformate Injection". Sodium Phosphonoformate Injection is used for Cytomegalovirus Retinitis in AIDS patients and Acyclovir-resistant Herpes Simplex Virus cutaneous and mucous membrane infection in patients with immune function damage.
Huaren Pharmaceutical's (SZSE:300110) Conservative Accounting Might Explain Soft Earnings
Investors Give Huaren Pharmaceutical Co., Ltd. (SZSE:300110) Shares A 30% Hiding
